December 11, 2009, Newsletter Issue #50: What is the consensus of the medical community regarding Bextra?
Tip of the Week
Studies suggesting possible dangerous side effects of COX-2 inhibitors such as Bextra remain inconclusive and even contradictory. However, there is enough evidence that the FDA has made the following interim recommendations: Physicians prescribing Celebrex or Bextra , should consider this information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal bleeding, have a history of intolerance to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs), or are not doing well on non-selective NSAIDs may be appropriate candidates for COX-2 selective agents. Risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account on an individual basis.
About LifeTips
Now one of the top on-line publishers in the world, LifeTips offers tips to millions of monthly visitors. Our mission mission is to make your life smarter, better, faster and wiser. Expert writers earn dough for what they know. And exclusive sponsors in each niche topic help us make-it-all happen.
